Coronavirus Disease 2019: The Role of the Fibrinolytic System from Transmission to Organ Injury and Sequelae.
作者信息
Kwaan Hau C
机构信息
Division of Hematology-Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
出版信息
Semin Thromb Hemost. 2020 Oct;46(7):841-844. doi: 10.1055/s-0040-1709996. Epub 2020 May 9.
Abstract
摘要
相似文献
1
Coronavirus Disease 2019: The Role of the Fibrinolytic System from Transmission to Organ Injury and Sequelae.
Semin Thromb Hemost. 2020 Oct;46(7):841-844. doi: 10.1055/s-0040-1709996. Epub 2020 May 9.
2
Circulating Plasminogen Concentration at Admission in Patients with Coronavirus Disease 2019 (COVID-19).
Semin Thromb Hemost. 2020 Oct;46(7):859-862. doi: 10.1055/s-0040-1715454. Epub 2020 Sep 3.
3
Thrombosis and Hemostasis Issues in Cancer Patients with COVID-19.
Semin Thromb Hemost. 2020 Oct;46(7):785-788. doi: 10.1055/s-0040-1714275. Epub 2020 Aug 12.
4
Incidence of heparin-induced thrombocytopenia in patients with 2019 coronavirus disease.
Med Clin (Barc). 2020 Nov 13;155(9):409-410. doi: 10.1016/j.medcli.2020.05.041. Epub 2020 Jul 28.
5
Plasmacytoid lymphocytes in SARS-CoV-2 infection (Covid-19).
Am J Hematol. 2020 Jul;95(7):861-862. doi: 10.1002/ajh.25834. Epub 2020 Apr 28.
6
Coronavirus Disease 2019 Coagulopathy: Disseminated Intravascular Coagulation and Thrombotic Microangiopathy-Either, Neither, or Both.
Semin Thromb Hemost. 2020 Oct;46(7):781-784. doi: 10.1055/s-0040-1712156. Epub 2020 Jun 8.
7
COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation.
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620938149. doi: 10.1177/1076029620938149.
8
Free-floating right heart thrombus with pulmonary embolism in SARS-CoV-2 patient.
Med Clin (Barc). 2020 Nov 13;155(9):415-416. doi: 10.1016/j.medcli.2020.06.014. Epub 2020 Jul 4.
9
Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow's triad.
Clin Rheumatol. 2020 Sep;39(9):2529-2543. doi: 10.1007/s10067-020-05275-1. Epub 2020 Jul 11.
10
Thrombolysis restores perfusion in COVID-19 hypoxia.
Br J Haematol. 2020 Sep;190(5):e270-e274. doi: 10.1111/bjh.17050. Epub 2020 Aug 17.
引用本文的文献
1
Potential Nephroprotective Effect of uPA against Ischemia/Reperfusion-Induced Acute Kidney Injury in αMUPA Mice and HEK-293 Cells.
Biomedicines. 2024 Oct 12;12(10):2323. doi: 10.3390/biomedicines12102323.
2
Transcriptomic analysis of profibrinolytic and fibrinolytic inhibitor genes in COVID-19 patients.
Narra J. 2024 Aug;4(2):e843. doi: 10.52225/narra.v4i2.843. Epub 2024 Jul 5.
3
Aprotinin (II): Inhalational Administration for the Treatment of COVID-19 and Other Viral Conditions.
Int J Mol Sci. 2024 Jun 29;25(13):7209. doi: 10.3390/ijms25137209.
4
Fibrinolytic system and COVID-19: From an innovative view of epithelial ion transport.
Biomed Pharmacother. 2023 Jul;163:114863. doi: 10.1016/j.biopha.2023.114863. Epub 2023 May 9.
5
Status of major hemostatic components in the setting of COVID-19: the effect on endothelium, platelets, coagulation factors, fibrinolytic system, and complement.
Ann Hematol. 2023 Jun;102(6):1307-1322. doi: 10.1007/s00277-023-05234-1. Epub 2023 Apr 19.
6
The potential impact of Covid-19 on the capacity of routine laboratory tests to detect heparin-induced thrombocytopenia.
Thromb J. 2022 Sep 26;20(1):55. doi: 10.1186/s12959-022-00411-0.
7
Dysregulated miRNAs network in the critical COVID-19: An important clue for uncontrolled immunothrombosis/thromboinflammation.
Int Immunopharmacol. 2022 Sep;110:109040. doi: 10.1016/j.intimp.2022.109040. Epub 2022 Jul 11.
8
Protection by metformin against severe Covid-19: An in-depth mechanistic analysis.
Diabetes Metab. 2022 Jul;48(4):101359. doi: 10.1016/j.diabet.2022.101359. Epub 2022 May 31.
9
Does COVID-19 infection increase the risk of pressure injury in critically ill patients?: A narrative review.
Medicine (Baltimore). 2022 Mar 18;101(11). doi: 10.1097/MD.0000000000029058.
10
Subacute dual stent thromboses in a COVID-19-positive patient.
Cardiovasc J Afr. 2022;33(6):329-332. doi: 10.5830/CVJA-2022-003. Epub 2022 Mar 24.
本文引用的文献
1
Is there a role for tissue plasminogen activator as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome?
J Trauma Acute Care Surg. 2020 Jun;88(6):713-714. doi: 10.1097/TA.0000000000002694.
2
Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis.
Eur Respir J. 2020 May 14;55(5). doi: 10.1183/13993003.00547-2020. Print 2020 May.
3
[A pathological report of three COVID-19 cases by minimal invasive autopsies].
Zhonghua Bing Li Xue Za Zhi. 2020 May 8;49(5):411-417. doi: 10.3760/cma.j.cn112151-20200312-00193.
4
The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.
Mil Med Res. 2020 Mar 13;7(1):11. doi: 10.1186/s40779-020-00240-0.
5
[Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia].
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):219-222. doi: 10.3760/cma.j.issn.1001-0939.2020.03.016.
6
Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer.
J Thorac Oncol. 2020 May;15(5):700-704. doi: 10.1016/j.jtho.2020.02.010. Epub 2020 Feb 28.
7
Clinical Characteristics of Coronavirus Disease 2019 in China.
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
8
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.
Lancet Respir Med. 2020 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24.
9
A pneumonia outbreak associated with a new coronavirus of probable bat origin.
Nature. 2020 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3.
10
Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus.
J Virol. 2020 Mar 17;94(7). doi: 10.1128/JVI.00127-20.
Zotero 插件